Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Ambrx Biopharma Inc.

Ambrx develops enhanced antibody-drug conjugates and employs expanded genetic code technology for potential cancer treatments. It focuses on precision biologics innovation.

	Dec '19	Dec '20	Dec '21	Dec '22
asset turnover	0.17 -	0.10 38.93%	0.03 68.09%	0.05 54.71%
cash per share	0.41 -	2.40 483.89%	8.31 246.23%	2.19 73.68%
company equity multiplier	1.85 -	-0.96 152.05%	1.21 225.43%	1.25 3.45%
days of inventory outstanding
days of payables outstanding
days of sales outstanding	49.24 -	26.22 46.75%	65.75 150.79%	101.09 53.74%
dividend yield
ebit per revenue	-2.18 -	-0.96 55.98%	-8.64 800.81%	-7.71 10.76%
ebt per ebit	0.99 -	1.36 36.97%	1.06 22.07%	1.33 25.71%
effective tax rate	0.00 -	-0.00 162.55%	-0.00 73.88%	-0.03 173,806.99%
enterprise value multiple	-30.92 -	-49.68 60.65%	-0.45 99.10%	-0.79 76.94%
fixed asset turnover	2.07 -	3.92 88.80%	0.47 87.89%	0.53 11.40%
free cash flow per share	-0.07 -	-0.55 640.42%	-2.34 323.08%	-1.81 22.79%
gross profit margin	1 -	1 0%	1 0%	1 0%
interest coverage				-58.97 -
inventory turnover
long term debt to capitalization	0.09 -	-0.01 113.30%	0.06 621.00%	0.08 32.41%
net income per ebt	1.00 -	1.00 0.01%	1.00 0.00%	1.03 2.55%
net profit margin	-2.16 -	-1.30 39.70%	-9.16 601.98%	-10.54 15.03%
operating cash flow per share	-0.07 -	-0.55 644.16%	-2.18 299.56%	-1.78 18.49%
operating profit margin	-2.18 -	-0.96 55.98%	-8.64 800.81%	-7.71 10.76%
payables turnover
pretax profit margin	-2.16 -	-1.30 39.71%	-9.16 602.01%	-10.28 12.18%
price fair value	19.22 -	-4.61 123.97%	0.97 121.11%	0.74 23.52%
receivables turnover	7.41 -	13.92 87.81%	5.55 60.13%	3.61 34.95%
return on assets	-0.36 -	-0.13 63.18%	-0.30 124.01%	-0.53 77.97%
return on capital employed	-0.48 -	-0.11 77.39%	-0.32 190.16%	-0.44 39.00%
return on equity	-0.67 -	0.13 119.16%	-0.36 380.97%	-0.66 84.11%
total debt to capitalization	0.12 -	-0.02 119.20%	0.06 375.79%	0.09 42.75%

COM:AMBRX

Ambrx

Last Close

27.98

06/03 21:00

Market Cap

1.77B

Beta: -

Volume Today

1.42M

Avg: -

Preview